Next Article in Journal
Chemotherapeutic Interventions Against Tuberculosis
Next Article in Special Issue
Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies
Previous Article in Journal
Removal of Cholera Toxin from Aqueous Solution by Probiotic Bacteria
Previous Article in Special Issue
Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins
Pharmaceuticals 2012, 5(7), 674-689; doi:10.3390/ph5070674

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab

1 Institute of Pathology, Oslo University Hospital, Rikshospitalet University of Oslo, Oslo 0027, Norway 2 Roche Diagnostics GmbH, Pharma Research Penzberg, Nonnenwald 2, Penzberg 82377, Germany 3 Department of Pathology, Oslo University Hospital, Rikshospitalet, Post Box 4950 Nydalen, Oslo 0424, Norway
* Author to whom correspondence should be addressed.
Received: 20 April 2012 / Revised: 13 June 2012 / Accepted: 21 June 2012 / Published: 28 June 2012
(This article belongs to the Special Issue Hsp90 Inhibitors)
View Full-Text   |   Download PDF [620 KB, uploaded 28 June 2012]   |   Browse Figures


ErbB2 is an important oncogenic protein involved in carcinogenesis of, among others, breast, gastric, and ovarian carcinoma. Over-expression of ErbB2 is found in almost 20% of breast cancers, and this results in proliferative and anti-apoptotic signalling. ErbB2 is therefore an important treatment target. Antibodies recognizing full-length ErbB2 are clinically established, and drugs targeting the ErbB2 stabilizing heat shock protein 90 (Hsp90) are under clinical evaluation. We have investigated effects of the ErbB2-binding antibodies trastuzumab and pertuzumab alone and in combination, as well as the effect of the antibodies in combination with the Hsp90 inhibitor 17-AAG. Our results confirm the notion that combination of different ErbB2-binding antibodies more efficiently down-regulates ErbB2 than does one antibody in isolation. Additionally, our data demonstrate that ErbB2 is most efficiently down-regulated upon incubation with anti-ErbB2 antibodies in combination with Hsp90 inhibitors. The combination of anti-ErbB2 antibodies, and especially the combination of antibodies with 17-AAG, did also increase the inhibition of Akt activation of either agent, which could suggest an anti-proliferative effect. In such case, combining these agents could be beneficial in treatment of tumors not responding to trastuzumab only.
Keywords: 17-AAG; pertuzumab; trastuzumab; Hsp90; ErbB2 17-AAG; pertuzumab; trastuzumab; Hsp90; ErbB2
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Hughes, J.B.; Rødland, M.S.; Hasmann, M.; Madshus, I.H.; Stang, E. Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab. Pharmaceuticals 2012, 5, 674-689.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert